Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension

Abstract

Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example:

What is claimed is:  
     
         1 . A conjugate comprising a residue of a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound, said conjugate being renal selective.  
     
     
         2 . Conjugate of  claim 1  comprising a first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by said biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue selectivity in the kidney.  
     
     
         3 . Conjugate of  claim 2  wherein said first and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.  
     
     
         4 . Conjugate of  claim 3  wherein said angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:  
       
         
           
           
               
               
           
         
         wherein m is a number selected from one to four, inclusive;  
         wherein each of R 1  through R 11  is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 16  and R 17  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula  
         wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each of R 33 , R 34 , R 35 , R 36 , R 37  and R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R 26  and R 27  taken together and R 28  and R 29  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 26  and R 27  taken together and R 31  and R 32  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety.  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         5 . Conjugate of  claim 4  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each of R 33  through R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically acceptable salt thereof.  
       
     
     
         6 . Conjugate of  claim 5  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive;  
         wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 40 , R 41 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39 , R 40 , R 41  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R 44  and R 45  may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, wherein R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl;  
         wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         7 . Conjugate of  claim 6  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         8 . Conjugate of  claim 7  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         9 . Conjugate of  claim 8  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties consisting of CO 2 H, CO 2 CH 3 , SH, CH 2 SH, C 2 H 4 SH, PO 3 H 2 , NHSO 2 CF 3 , NHSO 2 C 6 F 5 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , CONHOCH 3 , CONHOC 2 H 5 , CONHCF 3 , OH, CH 2 OH, C 2 H 4 OH, OPO 3 H 2 , OSO 3 H ,  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 46 , R 47  and R 48  is independently selected from H, Cl, CN, NO 2 , CF 3 , C 2 F 5 , C 3 F 7 , CHF 2 , CH 2 F, CO 2 CH 3 , CO 2 C 2 H 5 , SO 2 CH 3 , SO 2 CF 3  and SO 2 C 6 F 5 ; wherein Z is selected from O, S, NR 49  and CH 2 ; wherein R 49  is selected from hydrido, CH 3  and CH 2 C 6 H 5 ; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R 3  through R 11  so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from  
         
           
             
             
                 
                 
             
           
         
          and the esters, amides and salts of said acidic moieties;  
         with the proviso that at least one of said R 1  through R 24  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         10 . Conjugate of  claim 9  wherein m is one; wherein each of R 1  and R 2  is independently selected from amino, aminomethyl, aminoethyl, aminopropyl, CH 2 OH, CH 2 OCOCH 3 , CH 2 Cl, Cl, CH 2 OCH 3 , CH 2 OCH(CH 3 ) 2 , I, CHO, CH 2 CO 2 H, CH(CH 3 )CO 2 H, NO 2 , Cl,  
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       —CO 2 CH 3 , —CONH 2 , —CONHCH 3 , CON(CH 3 ) 2 , —CH 2 —NHCO 2 C 2 H 5 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 NHCO 2 CH 3 , —CH 2 NHCO 2 C 3 H 7 , —CH 2 NHCO 2 CH 2 (CH 3 ) 2 , —CH 2 NHCO 2 C 4 H 9 , CH 2 NHCO 2 -adamantyl, —CH 2 NHCO 2 -(1-napthyl), —CH 2 NHCONHCH 3 , —CH 2 NHCONHC 2 H 5 , —CH 2 NHCONHC 3 H 7 , —CH 2 NHCONHC 4 H 9 , —CH 2 NHCONHCH(CH 3 ) 2 , —CH 2 NHCONH(1-napthyl), —CH 2 NHCONH(1-adamantyl), CO 2 H,  
       
         
           
           
               
               
           
         
       
       —CH 2 CH 2 CH 2 CO 2 H, —CH 2 CH 2 F, —CH 2 OCONHCH 3 , —CH 2 OCSNHCH 3 , —CH 2 NHCSOC 3 H 7 , —CH 2 CH 2 CH 2 F, —CH 2 ONO 2 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 SH,  
       
         
           
           
               
               
           
         
       
       H, Cl, NO 2 , CF 3 , CH 2 OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R 3  through  11  is hydrido, with the proviso that at least one of R 5 , R 6 , R 8  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         11 . Conjugate of  claim 10  wherein m is one; wherein R 1  is selected from amino, aminomethyl, aminoethyl, aminopropyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein R 2  is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R 3 , R 4 , R 6 , R 7 , R 8 , R 10 , and R 11  is hydrido; wherein one of R 5  and R 9  is hydrido and the other of R 5  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         12 . Conjugate of  claim 3  wherein said second residue forms a kidney-enzyme-cleavable amide bond with the residue of said angiotensin II antagonist compound.  
     
     
         13 . Conjugate of  claim 3  wherein said second residue is preferably selected from a class of compounds of Formula II:  
       
         
           
           
               
               
           
         
         wherein each of R 50  and R 51  may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, —OR 52 , —SR 53  and  
         
           
             
             
                 
                 
             
           
         
         with each of R 52 , R 53  and R 54  independently selected from alkyl; and wherein R 54  may be further selected from hydrido; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.  
       
     
     
         14 . Conjugate of  claim 13  wherein each G substituent is hydroxy.  
     
     
         15 . Conjugate of  claim 14  wherein each G substituent is hydroxy; wherein R 50  is hydrido; and wherein R 51  is selected from  
       
         
           
           
               
               
           
         
       
       wherein R 55  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.  
     
     
         16 . Conjugate of  claim 15  wherein said second residue is  
       
         
           
           
               
               
           
         
       
     
     
         17 . Conjugate of  claim 3  wherein said first residue is a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.  
     
     
         18 . Conjugate of  claim 3  wherein said first residue is provided by a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.  
     
     
         19 . Conjugate of  claim 18  wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diamino-terminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue so as to form a hydrolyzable amide bond.  
     
     
         20 . Conjugate of  claim 19  wherein said diamino-terminated linker group is a divalent radical of Formula III:  
       
         
           
           
               
               
           
         
       
       wherein each of R 200  and R 201  may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.  
     
     
         21 . Conjugate of  claim 20  wherein each of R 200  and R 201  is hydrido.  
     
     
         22 . Conjugate of  claim 19  wherein said diamino-terminated linker group is a divalent radical of Formula IV:  
       
         
           
           
               
               
           
         
         wherein each of Q and T is one or more groups independently selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 202  through R 205  is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.  
       
     
     
         23 . Conjugate of  claim 22  wherein said diamino-terminated linker group is a divalent radical of Formula V:  
       
         
           
           
               
               
           
         
       
       wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R 202  and R 203  is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R 202  or R 203  is attached in Formula V is not adjacent to a nitrogen atom of Formula V.  
     
     
         24 . Conjugate of  claim 23  wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.  
     
     
         25 . Conjugate of  claim 24  wherein each of R 202  and R 203  is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.  
     
     
         26 . Conjugate of  claim 25  wherein each of R 202  and R 203  is hydrido; and wherein each of p and q is two.  
     
     
         27 . Conjugate of  claim 19  wherein said diamino-terminated linker group is a divalent radical of Formula VI:  
       
         
           
           
               
               
           
         
       
       wherein each of R 214  through R 217  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.  
     
     
         28 . Conjugate of  claim 27  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.  
     
     
         29 . Conjugate of  claim 28  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido and alkyl; and wherein p is two.  
     
     
         30 . Conjugate of  claim 29  wherein each of R 214 , R 215 , R 216  and R 217  is hydrido; and wherein p is two.  
     
     
         31 . Conjugate of  claim 11  wherein said angiotensin II antagonist compound is selected from the group consisting of 
 methyl 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylate;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, hydrazide;  
 4′-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-cyclohexylethyl))-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexanoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenylmethyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-benzoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 5-[4′-[(5-butyl-3-amino-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminoethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxy-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxymethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxyethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxypropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxybutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole; and  
 5-[4′-[[3-butyl-5-(4-carboxyethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole.  
 
     
     
         32 . Conjugate of  claim 21  which is N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide.  
     
     
         33 . Conjugate of  claim 17  which is N 2 -acetyl-N-[[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L-glutamine.  
     
     
         34 . Conjugate of  claim 21  which is N-acetyl-L-glutamic acid, 5-[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl-1H-1,2,4-traizol-3-yl]acetylhydrazide.  
     
     
         35 . A pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers or diluents and a therapeutically-effective amount of a renal-selective conjugate, said renal selective conjugate comprising a residue of a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound.  
     
     
         36 . The composition of  claim 35  comprising a first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by said biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue selectivity in the kidney.  
     
     
         37 . The composition of  claim 36  wherein said first and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.  
     
     
         38 . The composition of  claim 37  wherein said angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:  
       
         
           
           
               
               
           
         
         wherein m is a number selected from one to four, inclusive;  
         wherein each of R 1  through R 11  is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 16  and R 17  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each of R 33 , R 34 , R 35 , R 36 , R 37  and R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R 26  and R 27  taken together and R 28  and R 29  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 26  and R 27  taken together and R 31  and R 32  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety.  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         39 . The composition of  claim 38  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, hetetoaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each of R 33  through R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         40 . The composition of  claim 39  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive;  
         wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 40 , R 41 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39 , R 40 , R 41  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R 44  and R 45  may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, wherein R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl;  
         wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         41 . The composition of  claim 40  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         42 . The composition of  claim 41  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected, from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         43 . The composition of  claim 42  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties consisting of CO 2 H, CO 2 CH 3 , SH, CH 2 SH, C 2 H 4 SH, PO 3 H 2 , NHSO 2 CF 3 , NHSO 2 C 6 F 5 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , CONHOCH 3 , CONHOC 2 H 5 , CONHCF 3 , OH, CH 2 OH, C 2 H 4 OH, OPO 3 H 2 , OSO 3 H,  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 46 , R 47  and R 48  is independently selected from H, Cl, CN, NO 2 , CF 3 , C 2 F 5 , C 3 F 7 , CHF 2 , CH 2 F, CO 2 CH 3 , CO 2 C 2 H 5 , SO 2 CH 3 , SO 2 CF 3  and SO 2 C 6 F 5 ; wherein Z is selected from O, S, NR 49  and CH 2 ; wherein R 49  is selected from hydrido, CH 3  and CH 2 C 6 H 5 ; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R 3  through R 11  so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from  
         
           
             
             
                 
                 
             
           
         
          and the esters, amides and salts of said acidic moieties;  
         with the proviso that at least one of said R 1  through R 24  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         44 . The composition of  claim 43  wherein m is one; wherein each of R 1  and R 2  is independently selected from amino, aminomethyl, aminoethyl, aminopropyl, CH 2 OH, CH 2 OCOCH 3 , CH 2 Cl, Cl, CH 2 OCH 3 , CH 2 OCH(CH 3 ) 2 , I, CHO, CH 2 CO 2 H, CH(CH 3 )CO 2 H, NO 2 , Cl,  
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       —CO 2 CH 3 , —CONH 2 , —CONHCH 3 , CON(CH 3 ) 2 , —CH 2 —NHCO 2 C 2 H 5 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 NHCO 2 CH 3 , —CH 2 NHCO 2 C 3 H 7 , —CH 2 NHCO 2 CH 2 (CH 3 ) 2 , —CH 2 NHCO 2 C 4 H 9 , CH 2 NHCO 2 -adamantyl, —CH 2 NHCO 2 -(1-napthyl), —CH 2 NHCONHCH 3 , —CH 2 NHCONHC 2 H 5 , —CH 2 NHCONHC 3 H 7 , —CH 2 NHCONHC 4 H 9 , —CH 2 NHCONHCH(CH 3 ) 2 , —CH 2 NHCONH(1-napthyl), —CH 2 NHCONH(1-adamantyl), CO 2 H,  
       
         
           
           
               
               
           
         
       
       —CH 2 CH 2 CO 2 H, —CH 2 CH 2 F, —CH 2 OCONHCH 3 , —CH 2 OCSNHCH 3 , —CH 2 NHCSOC 3 H 7 , —CH 2 CH 2 CH 2 F, —CH 2 ONO 2 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 SH,  
       
         
           
           
               
               
           
         
       
       H, Cl, NO 2 , CF 3 , CH 2 OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R 3  through  11  is hydrido, with the proviso that at least one of R 5 , R 6 , R 8  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         45 . The composition of  claim 44  wherein m is one; wherein R 1  is selected from amino, aminomethyl, aminoethyl, aminopropyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein R 2  is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R 3 , R 4 , R 6 , R 7 , R 8 , R 10 , and R 11  is hydrido; wherein one of R 5  and R 9  is hydrido and the other of R 5  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         46 . The composition of  claim 37  wherein said second residue forms a kidney-enzyme-cleavable amide bond with the residue of said angiotensin II antagonist compound.  
     
     
         47 . The composition of  claim 37  wherein said second residue is preferably selected from a class of compounds of Formula II:  
       
         
           
           
               
               
           
         
       
       wherein each of R 50  and R 51  may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, —OR 52 , —SR 53  and  
       
         
           
           
               
               
           
         
       
       with each of R 52 , R 53  and R 54  independently selected from alkyl; and wherein R 54  may be further selected from hydrido; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.  
     
     
         48 . The composition of  claim 47  wherein each G substituent is hydroxy.  
     
     
         49 . The composition of  claim 48  wherein each G substituent is hydroxy; wherein R 50  is hydrido; and wherein R 51  is selected from  
       
         
           
           
               
               
           
         
       
       wherein R 55  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.  
     
     
         50 . The composition of  claim 49  wherein said second residue is  
       
         
           
           
               
               
           
         
       
     
     
         51 . Conjugate of  claim 37  wherein said first residue is provided by a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.  
     
     
         52 . The composition of  claim 37  wherein said first residue is provided by a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.  
     
     
         53 . The composition of  claim 52  wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diamino-terminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue so as to form a hydrolyzable amide bond.  
     
     
         54 . The composition of  claim 53  wherein said diamino-terminated linker group is a divalent radical of Formula III:  
       
         
           
           
               
               
           
         
       
       wherein each of R 200  and R 201  may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.  
     
     
         55 . The composition of  claim 54  wherein each of R 200  and R 201  is hydrido.  
     
     
         56 . The composition of  claim 53  wherein said diamino-terminated linker group is a divalent radical of Formula IV:  
       
         
           
           
               
               
           
         
         wherein each of Q and T is one or more groups independently selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 202  through R 205  is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.  
       
     
     
         57 . The composition of  claim 56  wherein said diamino-terminated linker group is a divalent radical of Formula V:  
       
         
           
           
               
               
           
         
       
       wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R 202  and R 203  is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R 202  or R 203  is attached in Formula V is not adjacent to a nitrogen atom of Formula V.  
     
     
         58 . The composition of  claim 57  wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.  
     
     
         59 . The composition of  claim 58  wherein each of R 202  and R 203  is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.  
     
     
         60 . The composition of  claim 59  wherein each of R 202  and R 203  is hydrido; and wherein each of p and q is two.  
     
     
         61 . The composition of  claim 53  wherein said diamino-terminated linker group is a divalent radical of Formula VI:  
       
         
           
           
               
               
           
         
       
       wherein each of R 214  through R 217  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.  
     
     
         62 . The composition of  claim 61  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.  
     
     
         63 . The composition of  claim 62  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido and alkyl; and wherein p is two.  
     
     
         64 . The composition of  claim 63  wherein each of R 214 , R 215 , R 216  and R 217  is hydrido; and wherein p is two.  
     
     
         65 . The composition of  claim 45  wherein said angiotensin II antagonist compound is selected from the group consisting of 
 methyl 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylate;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, hydrazide;  
 4′-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-cyclohexylethyl))-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexanoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenylmethyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-benzoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 5-[4′-[(5-butyl-3-amino-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminoethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxy-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxymethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxyethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxypropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxybutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole; and  
 5-[4′-[[3-butyl-5-(4-carboxyethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole.  
 
     
     
         66 . The composition of  claim 55  wherein said angiotensin II antagonist compound is N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide.  
     
     
         67 . The composition of  claim 51  wherein said angiotensin II antagonist compound is N 2 -acetyl-N-[[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L-glutamine.  
     
     
         68 . The composition of  claim 55  wherein said angiotensin II antagonist compound is N-acetyl-L-glutamic acid, 5-[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl-1H-1,2,4-traizol-3-yl]acetylhydrazide.  
     
     
         69 . A method for treating a circulatory disorder, said method comprising administering to a patient afflicted with or susceptible to said disorder a therapeutically-effective amount of a renal-selective conjugate, said renal-selective conjugate comprising a residue of a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound.  
     
     
         70 . The method of  claim 69  comprising a first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by said biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue selectivity in the kidney.  
     
     
         71 . The method of  claim 70  wherein said first and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.  
     
     
         72 . The method of  claim 71  wherein said angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:  
       
         
           
           
               
               
           
         
         wherein m is a number selected from one to four, inclusive;  
         wherein each of R 1  through R 11  is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 16  and R 17  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 12  and R 13  taken together, R 14  and R 15  taken together, R 19  and R 20  taken together and R 21  and R 22  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is oxygen atom or sulfur atom;  
         wherein each of R 33 , R 34 , R 35 , R 36 , R 37  and R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R 26  and R 27  taken together and R 28  and R 29  taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 26  and R 27  taken together and R 31  and R 32  taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety.  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         73 . The method of  claim 72  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, and R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is further independently selected from amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each of R 33  through R 38  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         74 . The method of  claim 73  wherein m is one; wherein each of R 1  through R 11  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom or sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         and wherein each of R 3  through R 11  may be further independently selected from hydroxy and from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive;  
         wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 40 , R 41 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39 , R 40 , R 41  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R 44  and R 45  may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         and wherein any of the foregoing R 1  through R 24 , Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each of R 25 , R 26 , R 27 , R 28  and R 29  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR 30  and  
         
           
             
             
                 
                 
             
           
         
         wherein D is selected from oxygen atom and sulfur atom, wherein R 30  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl;  
         wherein each of R 25 , R 26 , R 27 , R 28 , R 29 , R 31  and R 32  is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         75 . The method of  claim 74  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R 44  and R 45  taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R 44  and R 45  taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         76 . The method of  claim 75  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R 1  through R 11  may be further independently selected from amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties of the formula 
         —Y n A 
         wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42  and R 43  is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R 39  and R 42  may be further independently selected from amino radical of the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 44  and R 45  is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;  
         wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R 3  through R 11  or may be attached at any two adjacent positions selected from R 3  through R 11  so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;  
         wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;  
         wherein each of R 1  through R 11 , Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;  
         with the proviso that at least one of said R 1  through R 24 , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         77 . The method of  claim 76  wherein m is one; wherein each of R 1  and R 2  is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula  
       
         
           
           
               
               
           
         
         wherein X is selected from oxygen atom and sulfur atom;  
         wherein each n is a number independently selected from zero to six, inclusive;  
         wherein each of R 12  through R 24  is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;  
         wherein each of R 3  through R 11  is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;  
         and wherein each of R 3  through R 11  may be an acidic moiety further independently selected from acidic moieties consisting of CO 2 H, CO 2 CH 3 , SH, CH 2 SH, C 2 H 4 SH, PO 3 H 2 , NHSO 2 CF 3 , NHSO 2 C 6 F 5 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , CONHOCH 3 , CONHOC 2 H 5 , CONHCF 3 , OH, CH 2 OH, C 2 H 4 OH, OPO 3 H 2 , OSO 3 H,  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 46 , R 47  and R 48  is independently selected from H, Cl, CN, NO 2 , CF 3 , C 2 F 5 , C 3 F 7 , CHF 2 , CH 2 F, CO 2 CH 3 , CO 2 C 2 H 5 , SO 2 CH 3 , SO 2 CF 3  and SO 2 C 6 F 5 ; wherein Z is selected from O, S, NR 49  and CH 2 ; wherein R 49  is selected from hydrido, CH 3  and CH 2 C 6 H 5 ; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R 3  through R 11  so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from  
         
           
             
             
                 
                 
             
           
         
          and the esters, amides and salts of said acidic moieties;  
         with the proviso that at least one of said R 1  through R 24  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         78 . The method of  claim 77  wherein m is one; wherein each of R 1  and R 2  is independently selected from amino, aminomethyl, aminoethyl, aminopropyl, CH 2 OH, CH 2 OCOCH 3 , CH 2 Cl, Cl, CH 2 OCH 3 , CH 2 OCH(CH 3 ) 2 , I, CHO, CH 2 CO 2 H, CH(CH 3 )CO 2 H, NO 2 , Cl,  
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       —CO 2 CH 3 , —CONH 2 , —CONHCH 3 , CON(CH 3 ) 2 , —CH 2 —NHCO 2 C 2 H 5 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 NHCO 2 CH 3 , —CH 2 NHCO 2 C 3 H 7 , —CH 2 NHCO 2 CH 2 (CH 3 ) 2 , —CH 2 NHCO 2 C 4 H 9 , CH 2 NHCO 2 -adamantyl, —CH 2 NHCO 2 -(1-napthyl), —CH 2 NHCONHCH 3 , —CH 2 NHCONHC 2 H 5 , —CH 2 NHCONHC 3 H 7 , —CH 2 NHCONHC 4 H 9 , —CH 2 NHCONHCH(CH 3 ) 2 , —CH 2 NHCONH(1-napthyl), —CH 2 NHCONH(1-adamantyl), CO 2 H,  
       
         
           
           
               
               
           
         
       
       —CH 2 CH 2 CH 2 CO 2 H, —CH 2 CH 2 F, —CH 2 OCONHCH 3 , —CH 2 OCSNHCH 3 , —CH 2 NHCSOC 3 H 7 , —CH 2 CH 2 CH 2 F, —CH 2 ONO 2 ,  
       
         
           
           
               
               
           
         
       
       —CH 2 SH,  
       
         
           
           
               
               
           
         
       
       H, Cl, NO 2 , CF 3 , CH 2 OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R 3  through  11  is hydrido, with the proviso that at least one of R 5 , R 6 , R 8  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         79 . The method of  claim 78  wherein m is one; wherein R 1  is selected from amino, aminomethyl, aminoethyl, aminopropyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein R 2  is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R 3 , R 4 , R 6 , R 7 , R 8 , R 10 , and R 11  is hydrido; wherein one of R 5  and R 9  is hydrido and the other of R 5  and R 9  is an acidic group selected from CO 2 H, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH,  
       
         
           
           
               
               
           
         
         wherein each of R 46  and R 47  is independently selected from Cl, CN, NO 2 , CF 3 , CO 2 CH 3  and SO 2 CF 3 ;  
         with the proviso that at least one of said R 1  through R 11  substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;  
         or a tautomer thereof or a pharmaceutically-acceptable salt thereof.  
       
     
     
         80 . The method of  claim 71  wherein said second residue forms a kidney-enzyme-cleavable amide bond with the residue of said angiotensin II antagonist compound.  
     
     
         81 . The method of  claim 71  wherein said second residue is preferably selected from a class of compounds of Formula II:  
       
         
           
           
               
               
           
         
       
       wherein each of R 50  and R 51  may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto,  13  OR 52 , —SR 53  and  
       
         
           
           
               
               
           
         
       
       with each of R 52 , R 53  and R 54  is independently selected from hydrido and alkyl; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.  
     
     
         82 . The method of  claim 81  wherein each G substituent is hydroxy.  
     
     
         83 . The method of  claim 82  wherein each G substituent is hydroxy; wherein R 50  is hydrido; and wherein R 51  is selected from  
       
         
           
           
               
               
           
         
       
       wherein R 55  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.  
     
     
         84 . The method of  claim 83  wherein said second residue is  
       
         
           
           
               
               
           
         
       
     
     
         85 . The method of  claim 71  wherein said first residue is a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.  
     
     
         86 . The method of  claim 71  wherein said first residue is provided by a biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.  
     
     
         87 . The method of  claim 86  wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diamino-terminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue so as to form a hydrolyzable amide bond.  
     
     
         88 . The method of  claim 87  wherein said diamino-terminated linker group is a divalent radical of Formula III:  
       
         
           
           
               
               
           
         
       
       wherein each of R 200  and R 201  may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.  
     
     
         89 . The method of  claim 88  wherein each of R 200  and R 201  is hydrido.  
     
     
         90 . The method of  claim 87  wherein said diamino-terminated linker group is a divalent radical of Formula IV:  
       
         
           
           
               
               
           
         
         wherein each of Q and T is one or more groups independently selected from  
         
           
             
             
                 
                 
             
           
         
         wherein each of R 202  through R 205  is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.  
       
     
     
         91 . The method of  claim 90  wherein said diamino-terminated linker group is a divalent radical of Formula V:  
       
         
           
           
               
               
           
         
       
       wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso,that when each of R 202  and R 203  is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R 202  or R 203  is attached in Formula V is not adjacent to a nitrogen atom of Formula V.  
     
     
         92 . The method of  claim 91  wherein each of R 202  and R 203  is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.  
     
     
         93 . The method of  claim 92  wherein each of R 202  and R 203  is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.  
     
     
         94 . The method of  claim 93  wherein each of R 202  and R 203  is hydrido; and wherein each of p and q is two.  
     
     
         95 . The method of  claim 87  wherein said diamino-terminated linker group is a divalent radical of Formula VI:  
       
         
           
           
               
               
           
         
       
       wherein each of R 214  through R 217  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.  
     
     
         96 . The method of  claim 95  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.  
     
     
         97 . The method of  claim 96  wherein each of R 214  and R 215  is hydrido; wherein each of R 216  and R 217  is independently selected from hydrido and alkyl; and wherein p is two.  
     
     
         98 . The method of  claim 97  wherein each of R 214 , R 215 , R 216  and R 217  is hydrido; and wherein p is two.  
     
     
         99 . The method of  claim 79  wherein said angiotensin II antagonist compound is selected from the group consisting of 
 methyl 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][l,1′-biphenyl]-2-carboxylate;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, hydrazide;  
 4′-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-cyclohexylethyl))-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-cyclohexanoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-phenylmethyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(5-butyl-3-benzoyl-1,2,4,-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl)-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 4′-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-carboxylic acid;  
 5-[4′-[(5-butyl-3-amino-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminoethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-aminobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminophenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminocyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminomethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-aminoethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxy-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxymethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxyethyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxypropyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[(5-butyl-3-carboxybutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyphenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4-[[3-butyl-5-(4-carboxymethylphenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxyethylphenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxycyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole;  
 5-[4′-[[3-butyl-5-(4-carboxymethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole; and  
 5-[4′-[[3-butyl-5-(4-carboxyethylcyclohexyl)-1H-1,2,4-triazol-1-yl]methyl][1,1′-biphenyl]-2-yl]-1H-tetrazole.  
 
     
     
         100 . The method of  claim 89  wherein said renal-selective conjugate is N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide.  
     
     
         101 . The method of  claim 85  wherein said renal-selective conjugate is N 2 -acetyl-N-[[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L-glutamine.  
     
     
         102 . The method of  claim 89  wherein said renal-selective conjugate is N-acetyl-L-glutamic acid, 5-[5-butyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl-1H-1,2,4-traizol-3-yl]acetylhydrazide.  
     
     
         103 . The method of  claim 69  wherein said circulatory disorder is a hypertensive-related disorder.  
     
     
         104 . The method of  claim 103  wherein said hypertensive-related disorder is chronic hypertension.  
     
     
         105 . The method of  claim 69  wherein said circulatory disorder is a sodium-retaining disorder.  
     
     
         106 . The method of  claim 105  wherein said sodium-retaining disorder is congestive heart failure.  
     
     
         107 . The method of  claim 105  wherein said sodium-retaining disorder is cirrhosis.  
     
     
         108 . The method of  claim 105  wherein said sodium-retaining disorder is nephrosis.